Shalby Ltd (SHALBY) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported healthy improvement across key financial parameters, with consolidated revenue growing 11.6% year-on-year, although EBITDA growth was modest at 1%.
- The Med Tech business demonstrated strong performance, with a 53% YoY revenue increase, achieving its fourth consecutive quarter of positive consolidated EBITDA, signaling a positive turnaround and growing profitability.
- The hospital segment showed steady growth with a 7% YoY revenue increase, driven by a 9.8% rise in occupied beds and improved performance in key units like Krishna, Mohali, and Naroda.
- A significant milestone was achieved by the Shalby International (Gurgaon) unit, which reached EBITDA break-even for the first time since its acquisition, indicating a sustainable and growing profitability trajectory.
- The company continues to maintain a healthy balance sheet with a comfortable gearing ratio of 0.46x, while actively managing its debt profile through strategic replacement of facilities at a lower cost.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.